Home / Press Releases

Press Releases

Oct, 29, 2018 – Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL

Financing complements the €4.3 million raised in July 2017 and represents one of the largest immune-oncology financing rounds in Europe.

Oct, 17, 2017 – Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1

After a recent capital raise of 4.3 M€s another significant advance for Invectys

July 12, 2017 – 4,3 Millions d’Euros de levés pour initier la Phase II

Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux

May 24, 2017 – Invectys presents its INVAC-1 therapeutic vaccine Phase I results at ASCO in USA

Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA

April 26, 2017 – Invectys at the Third International Symposium on Immunotherapy

Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer Vaccine Institute).

Nov 29, 2016 – Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer

Le projet de recherche, dirigé par Invectys et labellisé par Medicen Paris Region, a permis d’optimiser et d’améliorer le candidat vaccin INVAC-1 pour accélérer les essais cliniques contre les tumeurs solides

July, 29, 2016 – Invectys dépose un brevet sur l’obtention d’anticorps contre un « immune-checkpoint » en oncologie

Ce brevet porte sur l’obtention d’anticorps contre un nouvel immune-checkpoint, visant à débloquer les défenses immunitaires et permettre ainsi au système immunitaire du patient de détruire les cellules cancéreuses

March 18, 2016 – New success for the therapeutic vaccine INVAC-1 for patients with cancer

With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy.

Jan 21, 2016 – Invectys raises a further 7 million euros to accelerate clinical development of its  therapeutic cancer vaccine

With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance.

Oct 30, 2015 – Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine

A new clinical hope in cancer immunotherapy.

May 12, 2015 – Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients 

A new clinical hope in cancer immunotherapy.

March 30, 2015 – Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine

With a total of 10 million euros raised, new premises, new labs and new equipment, Invectys is ready for the clinic.

Sept 29, 2014 – Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy

INVAC-1 is an anticancer candidate vaccine targeting telomerase activity in cancer cells.


Clic here to find the list of Invecty’s scientific publications